ATRAID: A Potential Drug Target and Biomarker for Apoptosis-Related Protein 3

Target Name: ATRAID

NCBI ID: G51374

ATRAID

ATRAID: A Potential Drug Target and Biomarker for Apoptosis-Related Protein 3

Apoptosis, the natural programmed cell death, has been a topic of interest in the scientific community due to its potential implications in various diseases, including cancer, neurodegenerative diseases, and systemic infarctions. The regulation of apoptosis is a complex process, and various proteins have been identified that play a crucial role in this process. One such protein is ATRAID (Apoptosis-related protein 3), which is a key regulator of apoptosis and has been identified as a potential drug target and biomarker.

In this article, we will discuss the biology of ATRAID, its functions in apoptosis, its potential as a drug target, and its potential as a biomarker for various diseases.

Biography of ATRAID

ATRAID is a 21-kDa protein that is expressed in various tissues, including brain, heart, and liver. It is a member of the superfamily of APC (apoptosis-proteasome complex) proteins, which are involved in the regulation of cell death via the apoptosis pathway.

ATRAID was identified as a potential drug target and biomarker due to its unique structure and its involvement in apoptosis. It has been shown to play a critical role in the regulation of apoptosis and has been shown to interact with various signaling pathways, including the TGF-β pathway.

Functions of ATRAID in Apoptosis

ATRAID is a key regulator of apoptosis, which is a process that is essential for the development and progression of various diseases. During apoptosis, ATRAID helps to maintain the integrity of the cell, ensuring that the cell's contents are released correctly and that the cell's shape is maintained until it undergoes physical or chemical damage.

ATRAID is involved in the regulation of apoptosis by activating the pro-apoptotic signaling pathway, which is critical for the development of apoptosis. Additionally, ATRAID is involved in the regulation of the anti-apoptotic signaling pathway, which helps to prevent apoptosis from occurring.

Potential as a Drug Target

ATRAID has been identified as a potential drug target due to its involvement in the regulation of apoptosis and its unique structure. Several studies have shown that blocking ATRAID can lead to the inhibition of apoptosis, which could make it an effective therapeutic approach for various diseases.

One of the potential mechanisms by which ATRAID can be blocked is by inhibiting the formation of the pro-apoptotic protein Bcl-2. Bcl-2 is a protein that has been shown to interact with ATRAID and can inhibit its activity. Therefore, inhibiting the formation of Bcl-2 could lead to the activation of ATRAID and the inhibition of apoptosis.

Another potential mechanism by which ATRAID can be blocked is by modulating the activity of the protein caspase-3. Caspase-3 is a protein that is involved in the regulation of apoptosis and has been shown to interact with ATRAID. Therefore, modulating the activity of caspase-3 could lead to the inhibition of ATRAID and the inhibition of apoptosis.

Potential as a Biomarker

ATRAID has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and systemic infarctions. The regulation of apoptosis is a critical process that is involved in the development and progression of these diseases, and therefore, changes in the regulation of apoptosis could be an indicator of the presence of these diseases.

For example, in cancer, the regulation of apoptosis is often disrupted, leading to the failure of the immune system to control the growth and spread of the cancer. Therefore, evaluating the regulation of

Protein Name: All-trans Retinoic Acid Induced Differentiation Factor

Functions: Promotes osteoblast cell differentiation and terminal mineralization. Plays a role in inducing the cell cycle arrest via inhibiting CCND1 expression in all-trans-retinoic acid (ATRA) signal pathway. In osteoclasts, forms a transporter complex with ATRAID for nitrogen-containg-bisphophonates (N-BPs) required for releasing N-BP molecules that have trafficked to lysosomes through fluid-phase endocytosis into the cytosol (PubMed:29745899)

The "ATRAID Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATRAID comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets